Long-Term Follow-Up of Cytostatic Intravesical Instillation in Patients with Superficial Bladder Carcinoma

1997 ◽  
Vol 31 (2) ◽  
pp. 153-159 ◽  
Author(s):  
Hartwig Schwaibold ◽  
Uwe Pichlmeier ◽  
Hans-Jörg Klingenberger ◽  
Hartwig Huland
Keyword(s):  
Bladder Carcinoma ◽  
Intravesical Instillation ◽  
Superficial Bladder Carcinoma ◽  
Long Term Follow Up

Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients

Cancer ◽  
1994 ◽  
Vol 74 (10) ◽  
pp. 2819-2827 ◽  
Author(s):  
Alan Pollack ◽  
Gunar K. Zagars ◽  
Colin P. Dinney ◽  
David A. Swanson ◽  
Andrew C. von Eschenbach
Keyword(s):  
Prognostic Factors ◽  
Bladder Carcinoma ◽  
Preoperative Radiotherapy ◽  
Long Term Follow Up ◽  
Muscle Invasive

Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up

1994 ◽  
Vol 26 (4) ◽  
pp. 437-442 ◽  
Author(s):  
R. Minervini ◽  
R. Felipetto ◽  
L. Vigano ◽  
M. Cecchi
Keyword(s):  
Mitomycin C ◽  
Bladder Carcinoma ◽  
Carcinoma In Situ ◽  
Long Term Follow Up

Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma

Cancer ◽  
2000 ◽  
Vol 89 (5) ◽  
pp. 1089-1094 ◽  
Author(s):  
Margitta Retz ◽  
Jan Lehmann ◽  
Christian Trocha ◽  
Tillmann Loch ◽  
Ulrich Seppelt ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Locally Advanced ◽  
Combined Radiochemotherapy ◽  
Long Term Follow Up

Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy

2007 ◽  
Vol 14 (7) ◽  
pp. 591-594 ◽  
Author(s):  
Ken-Ichi Mori ◽  
Koichiro Nomata ◽  
Mitsuru Noguchi ◽  
Jiro Eguchi ◽  
Nobuyuki Hayashi ◽  
...  
Keyword(s):  
Bladder Carcinoma ◽  
Long Term Follow Up

Results at 5 years of intra vesical gemcitabine (G) single agent as adjuvant chemotheray in superficial transitional cell carcinoma (TCC) of the bladder

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16087-e16087
Author(s):  
F. Smaili ◽  
A. Bounedjar ◽  
R. Ferhat ◽  
K. Bouzid
Keyword(s):  
Bladder Carcinoma ◽  
Single Agent ◽  
Transitional Cell ◽  
Intravesical Instillation ◽  
Phase Iii ◽  
Intravesical Therapy ◽  
Superficial Bladder Carcinoma ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasion

e16087 Background: Systemic intravenous gemcitabine is usually used in advanced bladder carcinoma, intravesical G is a novel treatment approach for TCC. In this study we evaluate the efficacy of intravesical Gemcitabine in patients (pts) with superficial bladder carcinoma. Methods: From February 2003 to June 2004, 60 pts (57M/3F) were enrolled in the study (M/F = 57/3). The median age was 59,5 years old (24–84). Nine pts had a carcinoma in situ (Cis) and 51 had pT1 lesions. Three weeks after a total transurethral resection (TUR), patients receive intravesical instillation of 2000 mg G every week for 6 weeks, than every month for six months. They received a total of 720 instillations, Follow up was with cystoscopy and urine cytology every six months. Results: At a median follow-up time 60 months, all patients were evaluable for tumor response: 23(38, 3%) patient had a persistant complete remission after treatment, 26 patients (43,3%) had a superficial relapse of TCC, six patients (10%) had progressive disease: four with muscle invasion and two with distant metastasis. Conclusions: Intravesical therapy with gemcitabine is active and well tolerated treatment in patients with superficial TCC carcinoma of the bladder. A phase III trial comparing GEM with intravesical BCG or MMC is warranted No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document